Ah, the financial markets. A delicate ecosystem, perpetually teetering on the brink of euphoria or despair, often at the whim of a single tweet or an Oval Office pronouncement. In the ever-unpredictable world of President Donald J. Trump, this delicate balance is less a tightrope walk and more a high-wire act performed on a unicycle during a hurricane. The past few days, specifically November 6th and 7th, 2025, have offered a masterclass in market gymnastics, as investors grappled with a flurry of presidential activity ranging from obscure trade deals to life-saving drug price cuts, all while the Supreme Court pondered the very legality of his tariff empire. The result? A fascinating, if not entirely coherent, dance of stocks, bonds, and bluster.
The Art of the Deal… with Uzbekistan
Let’s start with the headline that undoubtedly sent shockwaves through… well, perhaps not Wall Street, but certainly the geopolitical punditry circuit. On Thursday, November 6th, President Trump proudly announced an “incredible Trade and Economic Deal” with Uzbekistan. According to the President, this Central Asian nation is poised to inject a staggering $35 billion into various U.S. sectors over the next three years, ballooning to over $100 billion in a decade, targeting everything from critical minerals to aviation and information technology. This follows earlier, equally impressive (and equally under-the-radar for most investors) agreements, such as Uzbekistan’s commitment to purchase up to 22 Boeing aircraft, a deal valued at more than $8 billion.
One might imagine the Dow Jones Industrial Average leaping to new heights, the Nasdaq Composite soaring on the wings of future IT contracts, and the S&P 500 doing a celebratory jig. Yet, the market’s reaction to this monumental bilateral agreement with a nation of 35 million people was, to put it mildly, muted. In fact, specific, immediate market movements directly attributable to the Uzbekistan deal were conspicuously absent from the financial headlines. It seems that while the President is busy securing future prosperity in the steppes of Central Asia, the titans of finance remain fixated on slightly more… domestic dramas. Perhaps the market simply hasn’t grasped the strategic importance of Uzbek critical minerals yet. Or maybe, just maybe, it’s already priced in the inherent greatness of all Trumpian deals, rendering individual announcements mere footnotes in the grand saga of economic triumph.
Pills, Prices, and Presidential Prowess
Where the Uzbekistan deal failed to ignite the trading floors, a different kind of announcement certainly got pulses racing – particularly those of pharmaceutical executives and, presumably, anyone hoping to shed a few pounds. On Thursday, November 6th, President Trump unveiled landmark agreements with pharmaceutical giants Eli Lilly and Novo Nordisk, promising drastically reduced prices for their highly sought-after GLP-1 weight-loss drugs, including Wegovy, Zepbound, and Ozempic. The deal, touted under the administration’s “Most Favored Nation” policy, aims to make these “fat drugs” (as the President so eloquently put it) available for as little as $50 a month for Medicare beneficiaries (copay), with other eligible patients paying between $245 and $350 per month – a significant drop from the usual four-figure price tags.
In a classic display of quid pro quo, these pharmaceutical behemoths didn’t just agree to play ball out of the goodness of their corporate hearts. Eli Lilly committed to a hefty $27 billion investment in new U.S. manufacturing facilities, while Novo Nordisk pledged $10 billion. As a sweetener, both companies also secured a three-year reprieve from tariffs. The market’s reaction, however, was a tale of two drugmakers. Shares of Eli Lilly (LLY) traded about 1.3% higher on Thursday, capping an impressive 8% gain for the week, as analysts suggested the deal could solidify Lilly’s lead in the GLP-1 market, with expanded government coverage potentially offsetting any net price declines. Conversely, Novo Nordisk‘s U.S.-listed shares (NVO) took a hit, falling approximately 4% on Thursday and shedding 5% for the week. This dip was attributed, in part, to a revised, lower sales forecast from the Danish company and its ongoing bidding war with Pfizer (PFE) for obesity biotech Metsera. So, while some companies find favor in the pursuit of cheaper weight loss, others discover that even presidential endorsements come with a side of market indigestion.
Tariff Tango: SCOTUS Edition
Perhaps the most significant market mover of the week wasn’t a new deal, but the potential unraveling of an old policy. On Wednesday, November 5th, the Supreme Court heard arguments challenging the legality of President Trump’s sweeping tariffs, imposed under the International Emergency Economic Powers Act (IEEPA). The justices, including those appointed by Trump himself, appeared notably skeptical of the administration’s broad interpretation of its authority. This judicial skepticism sent a palpable ripple through the markets, but not in the way one might initially expect.
Instead of panic, Wall Street saw a rally. On Wednesday, the S&P 500 gained 0.4%, the Dow Jones Industrial Average (DJI) rose 0.5% to 47,311.00, and the Nasdaq Composite (IXIC) advanced 0.7%. Shares of companies considered “tariff-risk bellwethers” surged: Ford (F) and General Motors (GM) each climbed over 2%, while Caterpillar (CAT) advanced about 4%. Even the tech sector, a frequent target of trade anxieties, rebounded, with Advanced Micro Devices (AMD) up 2.5%, Broadcom (AVGO) rising 2%, and Micron Technology (MU) jumping approximately 9%. Alphabet (GOOGL) added 2.4% and Meta Platforms (META) gained 1.4%. The prevailing sentiment was that if the Supreme Court were to curb the President’s tariff powers, it might usher in a period of greater trade certainty, even if it meant potentially refunding billions in collected duties. The irony, of course, is that President Trump himself had declared this Supreme Court case “literally, LIFE OR DEATH for our Country” on Truth Social, asserting that tariffs were essential for record stock market highs. The market, it seems, had a different interpretation of “life or death” for its own bottom line.
Truth Social: The New Market Oracle?
Speaking of Truth Social, the President’s preferred megaphone continued to be a source of both policy announcements and market-moving pronouncements. Beyond the tariff drama, Trump’s posts often serve as a real-time barometer of his administration’s intentions and frustrations. Earlier in the week, following Democratic wins in key elections, Trump took to Truth Social, posting in all caps about the results, with reports noting that “market values tumble amid reports of…” While the full context of the market’s tumble isn’t provided in that snippet, it underscores the immediate, often volatile, impact of his digital missives. Past threats, such as those leveled against China in October 2025, saw the Nasdaq plunge 3.6%, Apple (AAPL) stock dive, and Nvidia (NVDA) lose nearly $229 billion in market capitalization.
The President also used the platform to threaten “another country” with military action, a recurring theme that, while not directly tied to market data in the latest alerts, certainly adds a layer of geopolitical uncertainty that investors have grown accustomed to navigating. His assertion that he ended a conflict between India and Pakistan within 24 hours by threatening tariffs, calling tariffs “a great national defence,” adds another colorful dimension to his trade policy philosophy. The market, in its infinite wisdom, seems to have developed a thick skin, often shrugging off these pronouncements unless they directly impact corporate earnings or global supply chains. It’s a testament to the market’s resilience, or perhaps its sheer exhaustion, that it continues to function amidst such a constant barrage of high-stakes rhetoric.
The Great Unwinding (and Rewinding)
The week concluded with a general market downturn on Thursday, November 6th. The Nasdaq dropped 1.9%, the S&P 500 lost 1.1%, and the Dow Jones Industrial Average slipped 0.8%. This broader sell-off was largely attributed to renewed concerns over “stretched AI valuations” and unsettling job data, which revealed 153,074 job cuts in October – the most for that month since 2003. Tech giants bore the brunt, with Palantir (PLTR) sinking 6.8%, Nvidia (NVDA) falling 3.7%, Amazon (AMZN) losing 2.9%, and Tesla (TSLA) dropping 3.5% ahead of a crucial shareholder vote. The ongoing 36-day government shutdown further muddied the waters, limiting reliable economic indicators and forcing investors to scrutinize every available private-sector report.
In essence, the market’s response to President Trump’s latest flurry of activity is a microcosm of his broader impact: a chaotic mix of policy shifts, bold claims, and unpredictable pronouncements. While a trade deal with Uzbekistan barely registered, the potential dismantling of his tariff regime by the Supreme Court brought a surprising surge of optimism. The drug price deals, a win for some companies and a setback for others, highlighted the transactional nature of his policy-making. And through it all, the broader economic currents – AI valuations, job numbers, and a government shutdown – continued to exert their gravitational pull, often overshadowing the presidential spectacle. The market, it seems, is a resilient beast, capable of both shrugging off grand pronouncements and reacting with surprising nuance to the shifting winds of policy and perception. One thing is certain: investing in the Trump era is never, ever boring.
DISCLAIMER: We read Trump’s posts so you don’t have to. This is comedy meets market data, not financial advice. Not political advice either – we just like charts and chaos.
Elana Harper is a seasoned financial editor and market analyst with over a decade of experience covering global equities, economic trends, and corporate earnings. Known for her sharp insights, Elana specializes in making complex financial topics accessible to a broad audience. She now serves as the Senior Financial Editor at Stock Market Watch, where she oversees daily market coverage and political commentary.